

## CURRICULUM VITAE

NAME: Michael Ludwig Coco  
President, Coco Communications, Inc.

PLACE OF BIRTH: Chicago, Illinois

MAILING ADDRESS: 1468 Willow Lake Drive, Suite C  
Atlanta, GA 30329

TELEPHONE: 404-248-9798

Email ADDRESS: [mlcoco@comcast.net](mailto:mlcoco@comcast.net)

### Education

1. Duke University, Durham, North Carolina; Doctor of Philosophy, Department of Pharmacology; August 1996.
2. Northern Illinois University, DeKalb, Illinois; Master of Arts, Department of Psychology (Biological Psychology); December 1987.
3. Northern Illinois University, DeKalb, Illinois; Bachelor of Arts/Bachelor of Science, Journalism/Psychology; May 1983.

### Professional Experience (Science)

1. Postdoctoral Fellow, Department of Psychiatry, Emory University, Atlanta, Georgia, 1996-1997.
2. Doctoral Candidate, Department of Pharmacology, Duke University, Durham, North Carolina, 1989-1996.
3. Instructor, Aurora University, Aurora, Illinois, 1987-1988.
4. Master of Arts Candidate, Department of Psychology, Northern Illinois University, DeKalb, Illinois, 1984-1987.
5. Teaching Assistant, Introduction to Psychology, Northern Illinois University, DeKalb, Illinois, 1986-1987.
6. Laboratory Assistant, Physiological Psychology, Northern Illinois University, DeKalb, Illinois, 1984-1986.

## Professional Experience (Writing)

### 1. Medical Writer (Consultant), various clients, 1998-present.

- Types of projects: Manuscripts, monographs, symposia proceedings, clinical study supplements, clinical aids, summaries of published clinical reports, content for CD programs, scripts (audio CDs/tapes, videotape, scripts for web-based programs and for CD-ROM/web-based game program), sales training materials (modules, slides and speaker notes, workshops, videotape scripts, web-based materials and questions), slide presentations, posters, abstracts, backgrounders, executive summaries, library research, proposals, consulting work toward preparation of a white paper.
- Topics:
  - *Cardiology*: ACE inhibitors and angiotensin II receptor blockers (ARBs) as treatment for hypertension, heart failure, and post-myocardial infarction; acute coronary syndromes; aging and hypertension; aldosterone blockers and heart failure; antiplatelet agents (thienopyridines), anticoagulants (warfarin) and reduction/prevention of atherothrombotic events; cardiac resynchronization therapy/biventricular pacing for congestive heart failure with intraventricular conduction delay; congestive heart failure; implantable cardioverter defibrillator (ICD) therapy; defibrillation mechanisms; treatments for dyslipidemia, including statins, niacin, fibrates, and combination products (Advicor and Vytorin); sudden cardiac death; synthetic oligosaccharide with antithrombotic effects; thrombosis and antithrombotic agents; use of thrombolytic agent to manage acute myocardial infarction and reduce heart failure incidence; race-based therapy for heart failure
  - *Endocrinology*: Anabolic steroid used for AIDS-related wasting; diabetes and oral hypoglycemic agents; diabetes and insulin therapy, including inhaled insulin; growth hormone therapy (adult and childhood GHD, chronic renal insufficiency, Turner syndrome, idiopathic short stature); hormone therapy (estrogen, estrogen/progestin, or SERMs) for signs/symptoms of menopause; LHRH antagonist for prostate cancer treatment (see oncology),
  - *Infectious diseases/allergies*: Various antibacterial drugs (lipopeptide, ketolides, macrolides, penicillins, fluoroquinolones, and glycopeptides); antibacterial drug resistance and prevention; treatment of HIV infection/various nucleoside reverse transcriptase inhibitors; treatment of alpha-herpesvirus infections; influenza virus and anti-influenza therapies; viral and fungal infections in transplantation; new antifungal agents; antifungal resistance; third-generation antihistamine for seasonal allergic rhinitis
  - *Neurology/anesthesiology*: Alzheimer's disease and its treatment; mechanisms of sleep and anti-insomnia therapies; antiepilepsy drugs (conventional and newer agents); newer antiepilepsy drug used for pain management; migraine and its treatment; MRI and multiple sclerosis; multiple sclerosis and its treatment; neuromuscular blocking agents; opioid analgesics for moderate-to-severe pain; opioid analgesics as part of balanced anesthesia; glucocorticoids and closed head trauma

- *Oncology*: Newer biologic or targeted therapies for cancer; treatment of metastatic colorectal cancer, lung cancer, chronic myeloid leukemia, renal cell carcinoma, gastrointestinal stromal tumors, and melanoma; COX-2 inhibitors in cancer treatment and prevention; LHRH antagonist as palliative treatment for prostate cancer (comparison with LHRH agonists and antiandrogens); pharmacologic management of chemotherapy- or radiotherapy-related nausea; pharmacologic management of chemotherapy-related anemia; angiogenesis, antiangiogenesis, and cancer
    - *Transplantation*: Immunosuppressive drugs used to prevent transplant rejection (general); chronic transplant rejection; calcineurin inhibitor-induced nephrotoxicity; cardiovascular risk, transplantation, and transplantation drugs; liver transplantation; pediatric renal transplantation; quality of life, transplantation, and transplantation drugs; racial/ethnic differences in ESRD and renal transplantation; transplantation and infection
    - *Other*: Crohn's disease (current project); over-the-counter proton-pump inhibitor used to treat frequent heartburn; skin diseases (psoriasis and atopic dermatitis) and their treatment; surfactant replacement therapy for premature infants; private versus public ownership of long-term care facilities.
2. Medical Writer (Full-time employee), ACCESS Medical Group, Ltd., Arlington Heights, Illinois, 1997-1998.
- Types of projects: Clinical study reports, CME monographs, manuscripts for publication, meeting abstracts, videotape scripts, white papers, executive summaries, poster construction and development of compendium booklets of posters exhibited at conferences, preparation of slide kits, newsletters, copy-editing.
  - Topics:
    - *Neurology*: Pharmaceutical treatment of epilepsy (general), newer antiepilepsy drug, conventional antiepilepsy drugs, prophylactic migraine treatment, pharmaceutical treatment of Parkinson's disease
    - *Cardiology*: Lipid-lowering agent (fibrin acid derivative), HMG CoA reductase inhibitors (ie, statins)
    - *Endocrinology*: Medicinal uses of anabolic steroids, hepatotoxicity related to anabolic steroid use, polycystic ovary syndrome
    - *Infectious diseases*: Advanced macrolide antibiotic
    - *Other*: Interactions between pharmaceutical agents and the cytochrome P450 enzyme system.
3. Medical Writer (Part-time freelance), 1996-1997.
- Monograph related to 22nd International Meeting on Epilepsy, held in Dublin, Ireland; in association with ACCESS Medical Group, Ltd.
  - Monograph related to Second European Congress of Epileptology, held in Den Haag, The Netherlands; in association with ACCESS Medical Group, Ltd.
4. Medical or science writing related to science training (see below), 1986-1997.
- Types of projects: Manuscripts, abstracts, posters, slide presentations, research proposals, copy-editing (of coworker's manuscripts), mock research grants.

- Topics: Coping, stress, and the mesolimbocortical dopamine system; neurotensin and stress; pharmacological characterization and localization of D<sub>3</sub> dopamine receptors; second messenger systems and neuroleptic drugs; protein synthesis and memory consolidation; Zif-268 protein and learning; effects of stress on blood cholesterol levels.

5. Writing unrelated to medicine or science, 1979-1981.

- Editorial editor, news editor, reporter; The Northern Star newspaper, Northern Illinois University, DeKalb, Illinois.

Professional Associations/Customers

1. Eighteen medical communications companies.
2. Twenty-seven pharmaceutical or biotechnology companies. (Abbott Laboratories; Amgen Inc.; Barr Laboratories; Bristol-Myers Squibb; Cubist Pharmaceuticals; Elan Pharmaceuticals; Eli Lilly & Company; Fujisawa Healthcare, Inc.; Genentech, Inc.; GlaxoSmithKline; GlaxoWellcome Inc.; Guidant; Merck & Co., Inc.; NitroMed, Inc.; Novartis Pharmaceuticals Corporation; Ortho-McNeil; Parke-Davis; Pfizer Inc.; Pharmacia & Upjohn; Procter & Gamble; Roche Pharmaceuticals; Sanofi-Synthelabo, Inc.; Serono, Inc.; Sepracor Inc.; SmithKline Beecham Pharmaceuticals; Unimed/Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals) [*Note that some of these companies have subsequently merged.*]

Pharmaceutical Agents/Products Written About

Accupril (quinapril); AmBisome (amphotericin B); Anadrol-50 (oxymetholone); Aranesp (darbepoetin alfa); Arixtra (fondaparinux); Augmentin XR (extra-strength amoxicillin plus clavulanate); Avastin (bevacizumab); Axert (almotriptan); Biaxin (clarithromycin); BiDil (isosorbide dinitrate-hydralazine hydrochloride); Cancidas (caspofungin); Capecitabine (Xeloda); Celebrex (celecoxib); CellCept (mycophenolate mofetil); Cenestin (synthetic conjugated estrogens); Cidecin (daptomycin); Combivir (lamivudine/zidovudine); Coumadin (warfarin); Depacon (valproate); Depakote (divalproex); Diastat (diazepam rectal gel); Diovan (valsartan); Diovan HCT (valsartan/hydrochlorothiazide); DisperMox (amoxicillin tablets for oral suspension); Estorra (esopiclone); Evista (raloxifene); Exelon (rivastigmine); Exubera (inhaled insulin); Famvir (famciclovir); Gabitril (tiagabine); Glivec/Gleevec (imatinib mesylate); Glucophage XR (extended release metformin); Glucovance (glyburide/metformin); Humatrope and HumatroPen (somatropin for injection); Ketek (telithromycin); Lipitor (atorvastatin); Luxiq (betamethasone valerate 0.12% foam); Kytril (granisetron); Metaglip (glipizide/metformin); Mivacron (mivacurium); Mylinax (cladribine); Nimbex (cisatracurium); Novantrone (mitoxantrone for injection concentrate); Nutropin (somatropin for injection); Nutropin AQ (somatropin for injection); Nutropin AQ Pen (somatropin for injection); Nutropin Depot (somatropin for injectable suspension); Olux (clobetasol propionate 0.05% foam); Plavix (clopidogrel); Plenaxis (abarelix); Pravachol (pravastatin); PrilosecOTC (omeprazole magnesium); Prograf (tacrolimus); Protropin (somatrem for injection); Rapamune (sirolimus); Relenza (zanamivir); Relpax (eletriptan); Retavase (reteplase); Rezulin (troglitazone);

Roxicodone (oxycodone); Saizen (somatropin for injection); Soltara (tecastemizole); Sutent (sunitinib malate); Tarceva (erlotinib); Tracrium (atracurium); Trizivir (lamivudine/zidovudine/abacavir); Ultiva (remifentanyl); Valtrex (valacyclovir); Xeloda (capecitabine); Xopenex (levalbuterol); Ziagen (abacavir); Zofran (ondansetron); Zonegran (zonisamide)

### Professional Societies

1. American Medical Writers Association, 1998-present.
2. Society for Neuroscience, 1989-2001.
3. American Association for the Advancement of Science, 1987-1997.

### Honors

1. NIH Pre-doctoral Training Fellowship, 1990-1992.
2. Travel Fellowship, The Graduate School, Duke University, 1990-91, 1994-95.

### Research Reports

1. Coco ML and Weiss JM. Neural substrates of coping behavior in the rat: possible importance of mesolimbocortical dopamine systems. *Behav Neurosci.* 2005;119(2):429-445.
2. Borsody MK and Coco ML. A hypothesis accounting for the inconsistent benefit of glucocorticoid therapy in closed head trauma. *Medical Hypotheses.* 2001;56(1):65-72.
3. Coco ML, Kuhn CM, Ely TD, and Kilts CD. Selective activation of mesoamygdaloid dopamine neurons by conditioned stress: attenuation by diazepam. *Brain Research.* 1992;590:39-47.
4. Kilts CD, Coco ML, Ely TD, Bissette G, and Nemeroff CB. Differential effects of conditioned and unconditioned stress on the neurotensin content of dopamine cell body groups of the ventral mesencephalon. *Annals of the New York Academy of Sciences.* 1992;668:266-276.

### Research Abstracts

1. Coco ML and Weiss JM. Differential expression of Fos protein in the ventral tegmental area of coping and non-coping rats. *Society for Neuroscience Abstracts.* 1995;21:1949.
2. Coco ML and Weiss JM. Differential expression of Fos protein in coping and non-coping rats. *Society for Neuroscience Abstracts.* 1994;20:375.

3. Coco ML and Kilts CD. Coupling of D<sub>3</sub>-like receptors to guanine nucleotide binding proteins: a quantitative autoradiography study. *Society for Neuroscience Abstracts*. 1992;18:1515.
4. Coco ML and Kilts CD. Pharmacological characterization of “D<sub>3</sub>” dopamine receptors in limbic and non-limbic areas of the rat brain by quantitative autoradiography. *Society for Neuroscience Abstracts*. 1991;17:820.
5. Coco ML and Kilts CD. Differential activation of populations of mesoamygdaloid dopamine neurons by conditioned stress: attenuation by diazepam. *Society for Neuroscience Abstracts*. 1990;16:1051.
6. Coover GD, Coco ML, and Briner WE. Cholesterol blood levels in rats are suppressed by acute stress. *Society for Neuroscience Abstracts*. 1986;12.